secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cibus, Inc. (CBUS)
CIK:        0001705843
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001628280-23-038235
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cibus Q3 2023 net loss $34.5M; cash runway only into early Q1 2024
------------------------------------------------------------------

- Net loss of $34.5M ($1.59 per share) vs. $6.0M a year ago; R&D spend jumped to $17.5M.
- Cash and equivalents $31.9M; company warns cash covers only planned ops into Q1 2024.
- Strategic realignment & cost cuts initiated to focus on late-stage traits; no revenue reported.
- Completed field trials for PSR canola, HT1/HT3 rice; returned edited germplasm to 2 of 10 customers.
- UK field trials for PSR in WOSR started; EU proposed gene-editing rules seen as favorable.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1705843/000162828023038235/0001628280-23-038235-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1705843/000162828023038235/cbus-20231109.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-038235

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer